Six patients suffering from chronic
liver disease attributed to
oxyphenisatin ingestion are presented. They seem to be the first such cases reported in France. These patients were between 22 and 69 years old, 5 of them were female. Three patients had a
chronic active hepatitis (CAH). In these three subjects the onset of the illness was a
jaundice ;
alanine transaminase (ALAT) exceeded 5 times the upper limit of the normal value ; smooth muscle
antibodies were present in 2 patients and
antinuclear antibodies in the third. Two other patients had
cirrhosis, without
chronic active hepatitis ; none presented
autoantibodies. The sixth patient suffered from a subacute
hepatitis, suggested by the presence of
jaundice and
ascites, high levels of serum ALAT and a very prolonged prothrombin time ; smooth muscle
antibodies were present. In all cases, HBs Ag was absent from serum. Each patient had ingested
laxative pills containing
oxyphenisatin for 4 to 25 years ; the total amount ingested was comprised between 12.5 and 350 g. The chronic
liver diseases reported in this series closely resemble those published in the literature. The lesions observed make it necessary to look for
oxyphenisatin ingestion in every patient having CAH or
cirrhosis without known etiology. These chronic
liver diseases imply the rapid withdrawal of
oxyphenisatin from french market, as already enforced in Australia and the United States.